Anthem Biosciences Q2 FY27 Results: Consolidated Net Profit ₹211 Crore on Total Income of ₹653 Crore
- Earnings
- Contract research and manufacturing (CRDMO) and specialty ingredients
Reviewed byRachit TripathiBlacklitt Research
Anthem Biosciences (NSE: ANTHEM) reported consolidated total income of ₹652.93 crore and net profit of ₹211.46 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. Standalone total income was ₹636.80 crore and standalone net profit ₹220.89 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹652.93 crore, up 9.1% YoY and 47.4% QoQ
- Net profit: ₹211.46 crore, up 21.9% YoY and 76.3% QoQ
- Net profit margin: 32.39%, up 3.40 percentage points YoY
- Finance costs: ₹3.31 crore, up 8.3% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹636.80 crore, up 5.1% YoY and 54.4% QoQ
- Net profit: ₹220.89 crore, up 11.3% YoY and 116.5% QoQ; basic EPS ₹3.92
- Net profit margin: 34.69%, up 1.94 percentage points YoY
- Other income: ₹64.70 crore, up 21.3% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 652.93 | 598.26 | +9.1% | 443.11 | +47.4% | |
| Revenue from operations | 594.03 | 550.50 | +7.9% | 418.22 | +42.0% |
| Other income | 58.90 | 47.75 | +23.3% | 24.89 | +136.6% |
| 211.46 | 173.43 | +21.9% | 119.94 | +76.3% | |
| Profit before tax | 296.37 | 229.60 | +29.1% | 144.58 | +105.0% |
| Finance costs | 3.31 | 3.06 | +8.3% | 0.89 | +273.2% |
| Depreciation | 30.71 | 33.50 | -8.3% | 29.99 | +2.4% |
| Tax expense | 84.91 | 56.18 | +51.2% | 24.64 | +244.6% |
| Net profit margin | 32.39% | 28.99% | +3.40 pp | 27.07% | +5.32 pp |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than income this quarter. Net profit rose 21.9% YoY against 9.1% growth in total income, and profit before tax rose 29.1%. Tax expense rose 51.2% to ₹84.91 crore, so the profit before tax growth was partly absorbed by tax.
Other income of ₹58.90 crore is 19.9% of profit before tax of ₹296.37 crore. Revenue from operations grew 7.9% YoY, slower than other income at 23.3%, so other income now makes up a larger share of the total.
Finance costs were ₹3.31 crore, or 0.5% of total income, against ₹3.06 crore a year earlier. The filing does not give reasons for the change in finance costs or in other income between quarters.
The consolidated results include the subsidiary Neoanthem Lifesciences Private Limited. Segment information covers CRDMO and Speciality Ingredients. Consolidated net profit of ₹211.46 crore is ₹9.43 crore lower than the standalone figure of ₹220.89 crore.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 636.80 | 606.02 | +5.1% | 412.44 | +54.4% | |
| Revenue from operations | 572.11 | 552.70 | +3.5% | 383.84 | +49.0% |
| Other income | 64.70 | 53.32 | +21.3% | 28.60 | +126.2% |
| 220.89 | 198.43 | +11.3% | 102.01 | +116.5% | |
| Profit before tax | 304.12 | 253.30 | +20.1% | 136.36 | +123.0% |
| Finance costs | 3.06 | 2.26 | +35.8% | 0.76 | +301.4% |
| Depreciation | 22.21 | 23.92 | -7.1% | 22.31 | -0.4% |
| Tax expense | 83.23 | 54.87 | +51.7% | 34.35 | +142.3% |
| Net profit margin | 34.69% | 32.74% | +1.94 pp | 24.73% | +9.95 pp |
| EPS, basic (₹) | 3.92 | n/a | n/a | n/a | n/a |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Revenue from operations grew 3.5%, while other income rose 21.3% to ₹64.70 crore, making up 10.2% of total income.
Standalone finance costs of ₹3.06 crore were up 35.8% on the year-earlier ₹2.26 crore, though they remain 0.5% of total income. The filing gives no reason for this change.
Standalone net profit of ₹220.89 crore compares with ₹102.01 crore in the previous quarter, a rise of 116.5%, against total income growth of 54.4%. The auditor's limited review reported no exceptions on either set of results.
The board recommended a final dividend for FY2025-26 of ₹2 per share, approved at the AGM on 22 Jul 2026. Employee stock option plan allotments were 1,670,909 shares in the June quarter and 143,285 shares in the September quarter, each of ₹2 face value.
Consolidated basic and diluted EPS could not be read reliably from the filing, so this article gives only the standalone basic EPS of ₹3.92.
Inference
The filing shows a final dividend of ₹2 per share, aggregating to ₹1,126.77 million, approved at the AGM on 22 Jul 2026, and a cash outflow for dividend paid in the half year. It does not say when the dividend was paid.
The filing does not state the reasons for the changes in finance costs or other income between quarters, or the company's plans for the business.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
